Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis
Key Points
This review aims to evaluate the efficacy and safety of anti-CLDN18.2 therapies in advanced cancers with CLDN18.2 positivity.
Conducted a systematic review and meta-analysis
Included studies on anti-CLDN18.2 therapies
Focused on gastric, gastro-oesophageal junction, and oesophageal carcinomas
Analyzed therapy efficacy and safety outcomes
Anti-CLDN18.2 therapies showed positive efficacy in patients with CLDN18.2 positivity
Meta-analysis results suggest improved treatment outcomes compared to conventional therapies
Abstract
www.crd.york.ac.uk/prospero identifier is CRD420251123719.
Like
Bookmark
Share
Like
Bookmark
Share
Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis | Synapse